Original Research Article

A comparison of intrathecal low dose Dexmedetomidine and clonidine as an adjuvant to bupivacaine in patients undergoing gynecological surgeries

Upasna V Bhatia1, Smitul Dave1,*, Renish Rafikbhai Hudda1

1 Dept. of Anaesthesia, AMC Met Medical College, LG Hospital, Ahmedabad, Gujarat, India

ARTICLE INFO

Article history:
Received 22-11-2019
Accepted 18-12-2019
Available online 28-02-2020

Keywords:
Dexmedetomidine
Clonidine
Bupivacaine
Spinal anaesthesia
Postoperative analgesia

ABSTRACT

Introduction: In the anquity of post-operative analgesia, the inception of α-2 adrenergic agonist agents in subarachnoid space with adjuvance to bupivacaine has opened new chapter.

Aims: The intent of the study was to compare the onset of duration of sensory and motor block, hemodynamic effects, post-operative analgesia and adverse effects of dexmedetomidine and clonidine with hyperbaric 0.5% bupivacaine for spinal anaesthesia.

Materials and Methods: Sixty adult patients received subarachnoid block either with Injection Bupivacaine (15mg) with clonidine (30μg) or Injection Bupivacaine (15mg) with Dexmedetomidine (10μg). Patients were monitored for variations in heart rate and noninvasive blood pressure after the spinal anaesthesia was given till the surgery got over every 5 minutes. Both the groups were compared for onset time for sensory block, time to reach sensory block to T10 and T6 level, time of regression of sensory block by 2 dermatomes and duration of analgesia.

Results: Mean Onset time of sensory block, time to reach T10 and T6 level was greater but not significant in Dexmedetomidine group but regression time of sensory block by 2 dermatomes was significantly higher in clonidine group, 100.21±2.58 minutes as compared to 80.43±3.45 in dexmedetomidine group. Onset time to reach bromage II was significantly faster in group BD (35.53±3.57seconds) as compared to Clonidine group (49.03±30.15seconds). Dexmedetomidine group patients had significantly (p<0.0001) higher duration of analgesia (589±5.5minutes) as compared to Group clonidine (507±4.8minutes). There was no sedation and no hemodynamic instability observed in either of the groups.

Conclusions: We conclude that though both Clonidine and Dexmedetomidine prolongs duration of sensory and motor block of Bupivacaine, But Dexmedetomidine is more appropriate as it provides better VAS score (quality) and longer duration of postoperative analgesia than clonidine.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by/4.0/)

1. Introduction

Postoperative diminution of pain is the sole essence of Anaesthesia. Ever since the introduction of local anaesthetics, Anaesthesiologists and physicians investigated different modes of using them. Spinal Anaesthesia has emerged as one of the important technique which is simple effective and safe with history since its introduction. Any drug when added to local anaesthetic agent intrathecally, forms reliable and reproducible method of postoperative analgesia. In the past various drugs has been used and opioids are among them which ineluctably does not cause motor or autonomic blockade. But presence of side effects like nausea vomiting, respiratory depression urinary retention incited further research towards non-opioid analgesics who are devoid of these side effects.

Many studies have undergone to improve the quality of subarachnoid block and found that α2 Adrenergic agonists are new such neuraxial adjuvants. Clonidine, an α2 Adrenergic receptor agonist has 200 : 1 times affinity ratio of α2: α1 receptors while Dexmedetomidine who is selective α2 Adrenergic receptor agonist has 620 : 1 respectively. Dexmedetomidine also displays protective and growth promoting properties in tissues which includes nerve
cells from cortex. It has neuroprotective effect similar to methylprednisolone when given in spinal cord injury.3,4

We compared the collegial effect of clonidine and Dexmedetomidine to hyperbaric bupivacaine when given intrathecally analogous to onset and duration of sensory and motor blockade analgesia and quality of VAS Score.

2. Materials and Methods

After obtaining approval from the Institutional ethical committee, a prospective randomized single blinded study was conducted in 60 patients of 18-65 yrs of ASA (American society of Anaesthesiologists) physical status I and II who were posted for elective Gynaecological surgeries (Table 2) in our Hospital from July 2019 to November 2019.

Patients belonging to ASA physical Status III and IV or patients having significant cardiovascular, renal or hepatic dysfunction, morbidly obese patients, or patients having allergy to drugs used or contraindication to subarachnoid block were excluded from the study.

Computer generated randomization was used to allocate the patients into 2 groups. Each comprising of 30 patients.

- **Group BC:** Patients received injection Bupivacaine 15mg with 30 µg clonidine
- **Group BD:** Patients received injection Bupivacaine 15mg with 10 µg dexmedetomidine

Informed consent from the patients were taken and then they were enlisted in the study. Patients were explained about Visual Analogue Scale score (VAS) in preoperative visit and again was repeated in the operating room. Patients were given tablet Ranitidine Hydrochloride 150 mg in the night previous to the surgery day. Patients were fasted overnight. Routine investigations which was advised in for preoperative visit was checked on the operative day.

In the operating room patients were preloaded with Ringer lactate 15ml/kg IV after securing the intravenous line with Intravenous cannula of 18 or 20 gauge. Monitors were applied and baseline vitals like Heart Rate (HR), Respiratory Rate (RR), ECG, O2 saturation (SpO2) and noninvasive Blood pressure (BP) were recorded. Subarachnoid block was given with spinal needle in L 2-3 space in sitting position using aseptic precautions and drug was injected in subarachnoid space after confirming the free flow and clear aspiration of CSF (cerebro - spinal fluid). Patients were made supine and following parameters were noted.

1. Time of onset and achieving T10 of sensory blockade
2. Onset Time of motor blockade
3. Time required to achieve Maximum sensory blockade
4. Sensory regression time by two segments
5. Intraoperative sedation scoring
6. Time when first rescue analgesia was given (total duration of analgesia)
7. Any adverse events like hypotension, bradycardia, pruritis, nausea vomiting or respiratory depression if occurred
8. Vital parameters

In our study appearance of tingling sensation in the limbs was taken to be onset of sensory analgesia and time to achieve T10 and highest segmental level reached was checked by pin prick method. Onset of motor block was determined by inability to raise extended limb but able to move legs and feet (stage II of modified Bromage criteria) was noted. Total duration of analgesia was defined as the time duration from the giving of spinal anaesthesia to first request of rescue analgesia (Injection Diclofenac Sodium 75 mg IV). Quality of analgesia was assessed by VAS. Motor blockade was assessed using modified Bromage scale. Sedation was assessed by Ramsay sedation scale and hemodynamic parameters (HR, mean arterial pressure (MAP), and SpO2) were recorded at 2 min interval up till 10 minutes and there after every 5 minutes till the surgery got over. Any adverse events like hypotension, bradycardia, nausea pruritis and respiratory depression were also recorded. Hypotension was defined when the blood pressure decreased ≥ 30% of the base line ; bradycardia was defined as decrease in heart rate ≥ 20% of the base line values.

2.1. Statistical analysis

Sample size was taken as 60. Data analysis was performed by using Statistical Package SPSS by Microsoft excel 2010. Data were expressed as mean ± standard deviation. Chi square test was used to identify the distribution of variables and continuous variables were analyzed by ANNOVA. Statistical significance was determined by subject t-test. Two tailed p values were used throughout and p value < 0.05 was taken as statistical significant with 1–ß 80% sensitivity.

3. Results

There was no analytical variance in patients ’ demographic datas, duration and type of surgery or ASA physical status as shown in Tables 1 and 2.

In our study we marked appearance of tingling sensation as onset of sensory blockade which was 10.76± 1.47 seconds in Group BC and 12.28± 6.97 seconds in Group BD. the disparity in both the groups was not significant with p value = 0.8202 suggesting insignificance. Table 3

Time to reach T10 dermatome 81.86 ± 7.74 seconds and 80.16 ± 43.21 seconds in group BC and BD respectively, difference again was analytically not significant (p=0.832) Table 3.

Time to reach T6 dermatome was 87.86±7.74 seconds in group BC and 86.03± 43.21 seconds in group BD with p=0.8202 suggesting insignificance. Table 3
Mean time of sensory regression by 2 segments was 100.21 ± 2.58 minutes in group BC whereas it was 80.43±3.45 minutes in group BD which was highly significant p<0.0001 Table 3.

Mean time of onset of motor block (Modified bromage scale II) was 49.03 ± 30.15 seconds in group BC whereas it was 35.53 ±3.57 seconds in group BD which was significant p=0.0180 Table 3.

Mean Time for rescue analgesia was 507 ±4.8 minutes in group BC and 589± 5.5 minutes in group BD.(highly significant) Table 3.

Maximum dermatome achieved: 16.66% patients achieved T4 dermatome and 83.33% achieved T6 level in group BC whereas 40% patients achieved T4 dermatome level and 60% patients achieved T6 dermatome in group BD. Table 4

Mean VAS Scores postoperatively at 2 hr was 0.166 in group BC and 0.36 ±0.49 in group BD which was significant and remained significant up till 6th hour postoperatively where mean VAS score was 2.8 ± 0.71 in group BC and was 2.83±0.37 which was not significant with p value 0.8381and thereafter it was significant again up till 11th hour as shown in Table 5. Mean VAS score at all times was 2.725 ±1.3 in group BC and 2.41 ± 1.8 in group BD which was highly significant p < 0.0001.

Adverse Events: 16.66% patients of group BC had bradycardia while only 10% patients experienced bradycardia in group BD. 20% patients in group BC had hypotension while only 6% in group BD, but 2 patients in group BC and one patient in group in BD patient was treated with single injection of mephentermine 6 mg IV and none of either group of patient required treatment for bradycardia. (Figure 1)

Mean heart rate was comparable in both the groups. Though the difference in the mean arterial blood pressure was significant after 30 minutes but the fall of Mean arterial blood pressure in individual group from baseline was not significant.

4. Discussion

One of the major goals of Anaesthesia is quelling of pain. With the technical skill and pharmacological knowledge anaesthesiologists are in paradigmatic position to treat pain during intraoperative and postoperative period and intent of good postoperative analgesia is to produce perennial, perdurable, continuous effective analgesia with minimal side effects. Hence an intrathecal additive to local anaesthetics forms dependable and predictable method to perpetuate the duration of anaesthesia with protracted post operative analgesia. Spinal Anaesthesia technique being simple and convenient has gained a wide recognition.

Dexmedetomidine and clonidine both are α₂ adrenoceptor agonists drugs which were initially used for treating hypertension and giving sedation and perceptibly the role of these two drugs unfurled in operation theatre for intraoperative and postoperative analgesia and sedation.

Al –Mustafa MM et al and Shagufta Naaz et al studied for the optimum dose of Dexmedetomidine and came to conclusion that there was significant prolongation of analgesia with nominal side effects when author used 10μg dexametomidine intrathecally as an adjuvant to hyperbaric Bupivacaine.

Kanazi et al found that there were minimal side effects and maximal prolongation of analgesia when clonidine was used in dose of 30 μg as an adjuvant to hyperbaric bupivacaine. So on the basis of these studies we adopted 10 μg Dexmedetomidine and 30μg of clonidine and evaluated their analgesic efficacy as adjuvants to 15mg hyperbaric bupivacaine when given intrathecally in patients posted for gynecological surgeries in our hospital.

The function of local anaesthetic is to block the sodium channels whereas α₂ adrenoceptor agonists by binding to presynaptic C-fibers and post synaptic dorsal neurons depresses its release by hyperpolarisation of post synaptic dorsal horn neurons. This explains how they prolong sensory block when combined to spinal anaesthetics.

In our study Group BC had earlier onset of sensory block at T10 and T6 dermatome than group BD and this was comparable to the studies conducted by Kanazi et al, Saxena et al and Shukla et al.

The maximum sensory level achieved in group BC (16.66%) and group BD (40%) was T4 which was in conconance with the studies conducted by Kanazi et al, Strebil et al and Gupta et al.

α₂ adrenoceptor agonists binds to motor neurons in the dorsal horns and thus resulting in the prolongation of motor block. In our study mean onset time of motor blockade was earlier in group BD which was significant and was in agreement with the study conducted by Saxena et al, Shukla et al and Grande et al.
Table 1: Demographic profile

|                | Mean ± SD | Group BC | Group BD | p value |
|----------------|-----------|----------|----------|---------|
| Age (yrs)      | 31.64 ± 9.12 | 30.82 ± 8.4 | 0.716    |
| ASA I:II       | 20:10     | 21:9     |          |         |
| BMI kg/m²      | 24.21 ± 2.21 | 23.24 ± 2.26 | 0.09     |
| Duration of surgery (min) | 87.33 ± 13.56 | 79.83 ± 19.58 | 0.08     |

Table 2: Type of surgeries

|                | Group BC | Group BD |
|----------------|----------|----------|
| AH             | 5        | 6        |
| VH             | 6        | 7        |
| Myomectomy     | 2        | 5        |
| Salpingo-Opherectomy | 1     | 2        |
| Ovaian mass    | 2        | 3        |
| VH + TOT       | 4        | 1        |
| VH + AP repair | 3        | 2        |
| p sling        | 3        | 2        |
| AH + salpingo-oopherectomy | 4    | 1        |
| Cystocele repair | 0       | 1        |
| Total          | 30       | 30       |

Table 3: Characteristics of spinal block

|                | Mean ±SD | Group BC | Group BD | p value |
|----------------|----------|----------|----------|---------|
| Sensory onset Seconds | 10.76 ± 1.47 | 12.83 ± 6.97 | 0.1169  |
| Time to reach T10 dermatome (seconds) | 81.86 ± 7.74 | 80.16 ± 43.21 | 0.8328  |
| Time to reach T6 dermatome (seconds) | 87.86 ± 7.74 | 86.03 ± 43.21 | 0.8202  |
| Time for 2 segment regression(minutes) | 100.21 ± 2.58 | 80.43 ± 3.45 | <0.0001 |
| Motor onset (seconds) | 49.03 ± 30.15 | 35.53 ± 3.57 | 0.0180  |
| Time for rescue analgesia (minutes) | 507 ± 4.8 | 589 ± 5.5 | <0.0001 |

Table 4: Maximum dermatome achieved

|            | Group BC | Group BD |
|------------|----------|----------|
| T4         | 5        | 16.66    |
| T6         | 25       | 83.33    |

Table 5: Mean VAS scores Postoperatively

|                | Mean ±SD Postoperatively | Group BC | Group BD | p value |
|----------------|--------------------------|----------|----------|---------|
| 1st Hour       | 0                        | 0        |          |         |
| 2nd hour       | 0.166 ± 0.37             | 0.36 ± 0.49 | <0.0001 |
| 3rd hour       | 1.13 ± 0.43              | 1 ± 0.10 | =0.1122 |
| 4th hour       | 2.03 ± 0.55              | 1.4 ± 0.50 | <0.0001 |
| 5th hour       | 2.73 ± 0.73              | 2 ± 0.10 | <0.0001 |
| 6th hour       | 2.8 ± 0.71               | 2.83 ± 0.37 | =0.8381 |
| 7th hour       | 3.76 ± 0.73              | 3.46 ± 0.50 | =0.0684 |
| 8th hour       | 4.44 ± 0.65              | 3.9 ± 0.48 | =0.0005 |
| 9th hour       | 4.75 ± 0.45              | 4.4 ± 0.50 | =0.0060 |
| 10th hour      | 4.68 ± 0.40              | 5.0      |         |
Time taken for regression of sensory blockade by 2 segments was earlier in group BD and was significantly more in group BC.

Both Dexmedetomidine and clonidine produces analgesia by activating $\alpha_2$ adrenoceptors in the spinal cord by reducing transmission of adrenoceptors nociceptive signals. Kalso $et$ al appealed that Dexmedetomidine has 10 times more affinity to $\alpha_2$ receptor than clonidine which can be seen in our study where group BD produces significantly longer duration of analgesia which is also in agreement with the study conducted by Grande $et$ al, Gupta $et$ al, Chhabra $et$ al and Abdel Hamid $et$ al.

Mean VAS scores were significantly lower at all times in the group BD than group BC suggesting better quality of post operative analgesia in group BD. Our study findings were comparable to the study done by Abdelhamid $et$ al and Ashtar Amin $et$ al.

$\alpha_2$ Agonists stimulate $\alpha_2$ receptors in the brain and spinal cord and inhibits neuronal firing which leads to hypotension and bradycardia. All patients in our study were preloaded with ringer lactate injection 15ml/kg, this could be the reason that despite the fall in blood pressure, Hypotension and Bradycardia was not appreciated in both the groups. It could be also be due to the dose selection of both the drugs (with minimal side effects).

The sedation effect of $\alpha_2$ agonists is postulated to be in the locus coruleus in the brainstem which is also origination site for descending medullospinal adrenergic pathways, key mechanisms in regulating nociceptive neurotransmission. Sedation was assessed using Ramsay sedation score at regular intervals and it was comparable in both the groups. All of the patients were in stage II, Patient were cooperative, oriented, and tranquil alert and none were anxious, agitated, or restless.

5. Conclusion
We conclude that though both Clonidine and Dexmedetomidine prolongs duration of sensory and motor block of Bupivacaine, But Dexmedetomidine is a better choice in terms quality and longer duration of postoperative analgesia.

6. Source of funding
None.

7. Conflict of interest
None.

References
1. Christiansson L. Update on adjuvants in regional anaesthesia. Period Biol. 2009;61:161–170.
2. Chaney MA. Side effects of intrathecal and epidural opioids. Can J Anaesth. 1995;42:891–903.
3. Sanders RD, Sun P, Patel S, Li M, Maze M. Dexmedetomidine provide cortical neuroprotection impact on anaesthetic induced neuroapoptosis in rat developing brain. Acta Anaesthesiol Scand. 2010;54:710–726.
4. Celik F, Gocmez C, Kamasak K, Tufek A, Guzel A, Toker O. The comparison of neuroprotective effect of intrathecal dexmedetomidine and methylprednisolone in spinal cord injury. Int J Surg. 2013;11:414–418.
5. Al-Mustafa MM, Abu-Halawehe SA, Alowedi AS, Mursheed MM, Ammari BA, $et$ al. Effect of Dexmedetomidine added to spinal bupivacaine for urological procedures. Saudi Med J. 2009;30:365–370.
6. Naaz S, Bandey J, Oizair, Asghar A. Optimal Dose of intrathecal Dexmedetomidinein lower abdominal surgeries in average Indian adult. J Clin Diagnostic Res. 2016;10:9–13.
7. Kanazi GE, Aouad MT, Jabour-Khouri SL, Jazzar MDA, Alameddine MM, $et$ al. Effect of low-dose Dexmedetomidine or Clonidine on the characteristics of Bupivacaine spinal block. Acta Anaesthesiol Scand. 2006;50:222–227.
8. Eisanach JC, Kock MD, Klimschka W, A. $et$ al. $\alpha_2$ adrenergic agonists for regional anaesthesia. Anesthesiol. 1996;85:655–674.
9. Lawhead RG, Blaxall HS, Bylund BD. Alpha-2A is the predominant $\alpha_2$ adrenergic receptor subtype in human spinal cord. Anesthesiol. 1992;77:983–991.
10. Smith MS, Schumba UB, Wilson KH. Alpha 2adrenergic receptor in humanspinal cord: specific localized expression of mRNA encoding alpha-2A adrenergic receptor subtypes at four distinct levels. Brain Res. 1995;34:109–117.
11. Yaksh TL, Jage J, Takano Y. Pharmacokinetics and pharmacodynamics of medullar agents. The spinal actions of $\alpha$-2 adrenergic agonists as analgesics. In: Atikenhead AR, Benad G, Brown BR, $et$ al., editors. Baillieres Clinical Anaesthesiology. vol. 3. London: Bailliere Tindall ; 1993. p. 597–614.
12. Fairbanke CA, Wilcox GL. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther. 1999;288:1107–1116.
13. Saxena H, Singh SK, Ghiidiyal S. Low dose intrathecal clonidine with bupivacaine improves onset and duration of block with haemodynamic stability. Internet J Anaesthesol. 2010;23:1–1.
14. Shukla D, Verma A, Agarwal A, Pandey HD, Tyagi C. Comparative study of intrathecal dexmedetomidine with intrathecal magnesium sulfate used as adjuvants to bupivacaine. J Anaesth Clin Pharmacol. 2011;27:495–499.
15. Strebel S, Gurzeler JA, Schneider MC, Aeschbach A, Kindler CH. Small dose intrathecal clonidine and isobaric bupivacaine for orthopedic surgery: A dose-response study. Anesth Analg. 2004;99:1231–1238.
16. Gupta R, Bogra J, Verma R, Kohli M, Kushwaha JK, Kumar S. Dexmedetomidine as an intrathecal adjuvant for postoperative analgesia. Indian J Anaesth. 2011;55:347–351.
17. Grandhe RP, Wig J, Yaddanapudi LN. Evaluation of bupivacaine-clonidine combination for unilateral spinal anesthesia in lower limb orthopedic surgery. J Anaesth Clin Pharmacol. 2008;24:155–158.
18. Kalso EA, Poyhia R, Rosenberg P. Spinal anti-nociception by dexmedetomidine, a highly selective $\alpha_2$- adrenergic agonist. Pharmacol Toxicol. 1991;68:140–143.
19. Chhabra AR, Jagtap SR, Dawoodi SF. Comparison of clonidine versus fentanyl as an adjuvant to intrathecal ropivacaine for major lower limb surgeries: A randomized double-blind prospective study. Indian J Pain. 2013;27:170–174.
20. Abdelhamid SA, Lakany MHE. Intrathecal dexmedetomidine: Usefullor not? J Anaesth Clin Res. 2013;4:351.
21. Mohamed A, Mohamed K, Abd-Elbaky S. Efficacy of Intrathecally Administered Dexmedetomidine Versus Dexmedetomidine with Fentanyl in Patients undergoing Major Abdominal Cancer Surgery. Pain Physician. 2012;15:339–348.

Author biography
Upasna V Bhatia Associate Professor
Smitul Dave Senior Resident

Renish Rafikbhai Hudda 1 Year Resident

Cite this article: Bhatia UV, Dave S, Hudda RR. A comparison of intrathecal low dose Dexmedetomidine and clonidine as an adjuvant to bupivacaine in patients undergoing gynecological surgeries. Indian J Clin Anaesth 2020;7(1):147-152.